Cited by 590Retinal Diseases and TreatmentsRetinal Imaging and AnalysisOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 43 of the 46 references it cites were found in a registry or an index.

Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials

Open access

Grunwald, Juan E., Daniel, Ebenezer, Huang, Jiayan, Ying, Gui-shuang, Maguire, Maureen G., Toth, Cynthia A., Jaffe, Glenn J., Fine, Stuart L., Blodi, Barbara, Klein, Michael L., Martin, Alison A., Hagstrom, Stephanie A., Martin, Daniel F.·2014·Ophthalmology

DOI 10.1016/j.ophtha.2013.08.015PMC PMC3892560

Open this paper in CoChat — free account Open PDF

Abstract

Purpose To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).Design Cohort within a randomized clinical trial.Participants We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.Methods Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).Main outcome measures Development of GA.Results By 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.Conclusions Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2013.08.015

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group* (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,783
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Self-citation
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20050701-14 · Cited by 912
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Relationship between RPE and Choriocapillaris in Age-Related Macular Degeneration
McLeod, D. S., Grebe, R. R., Bhutto, I. A., Merges, C. A., Baba, T., & Lutty, G. A. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3639 · Cited by 568

Show all 46 references

Sorted by citations

Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT
Sadda, S. R., Guymer, R. H., Holz, F. G., Schmitz-Valckenberg, S., Curcio, C. A., Bird, A. C., Blodi, B. A., Bottoni, F. G., Chakravarthy, U., Chew, E. Y., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.09.028 · Cited by 932
Self-citation
Molecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 563
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Age-related macular degeneration
Guymer, R. H., & Campbell, T. G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02609-5 · Cited by 541
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Wong, C. W., Yanagi, Y., Lee, W., Ogura, Y., Yeo, I. Y. S., Wong, T. Y., & Cheung, C. M. G. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.002 · Cited by 345
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen
Guymer, R. H., Markey, C. M., McAllister, I. L., Gillies, M. C., Hunyor, A. P., Arnold, J. J., Chang, A., Syed, A., Broadhead, G., Pham, T., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.11.025 · Cited by 317
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration
Wykoff, C. C., Croft, D. E., Brown, D. M., Wang, R., Payne, J. F., Clark, L., Abdelfattah, N. S., & Sadda, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.009 · Cited by 277
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K. B., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub4 · Cited by 280
Long-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials
Jaffe, G. J., Ying, G., Toth, C. A., Daniel, E., Grunwald, J. E., Martin, D. F., & Maguire, M. G. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.08.035 · Cited by 248
Self-citation
A new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration
Holz, F. G., Sadda, S. R., Staurenghi, G., Lindner, M., Bird, A. C., Blodi, B. A., Bottoni, F. G., Chakravarthy, U., Chew, E. Y., Csaky, K. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.12.002 · Cited by 251
Self-citation
Hydrogels in ophthalmic applications
Kirchhof, S., Göpferich, A. M., & Brandl, F. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.016 · Cited by 231
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials
Willoughby, A. S., Ying, G., Toth, C. A., Maguire, M. G., Burns, R. E., Grunwald, J. E., Daniel, E., Jaffe, G. J., Williams, D. F., Beardsley, S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.042 · Cited by 224
Self-citation
Structural and molecular changes in the aging choroid: implications for age-related macular degeneration
Chirco, K. R., Sohn, E. H., Stone, E. M., Tucker, B. A., & Mullins, R. F. (2016) · Eye · doi:10.1038/eye.2016.216 · Cited by 223
Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study
Bhisitkul, R. B., Mendes, T. S., Rofagha, S., Enanoria, W., Boyer, D. S., Sadda, S. R., & Zhang, K. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.032 · Cited by 210
Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Daniel, E., Ying, G.-S., Pan, W., Jaffe, G. J., Toth, C. A., Hagstrom, S. A., Maguire, M. G., & Martin, D. F. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.012 · Cited by 214
Self-citation
Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study)
Schmitz-Valckenberg, S., Sahel, J., Danis, R. P., Fleckenstein, M., Jaffe, G. J., Wolf, S., Prünte, C. F., & Holz, F. G. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.036 · Cited by 214
Self-citation
Activated Retinal Pigment Epithelium, an Optical Coherence Tomography Biomarker for Progression in Age-Related Macular Degeneration.
Curcio, C. A., Zanzottera, E. C., Ach, T., Balaratnasingam, C., & Freund, K. B. (2017) · PubMed Central · doi:10.1167/iovs.17-21872 · Cited by 212
Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Ying, G., Maguire, M. G., Daniel, E., & Martín, D. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.007 · Cited by 207
Self-citation
The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration
Jung, J. J., Chen, C. Y., Mrejen, S., Gallego‐Pinazo, R., Xu, L., Marsiglia, M., Boddu, S., & Freund, K. B. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.006 · Cited by 195
Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial
Rakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189
A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration
Schmidt-Erfurth, U. M., Klimscha, S., Waldstein, S. M., & Bogunović, H. (2016) · Eye · doi:10.1038/eye.2016.227 · Cited by 182
Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition
Crespo-Garcia, S., Tsuruda, P. R., Dejda, A., Ryan, R. D., Fournier, F., Chaney, S. Y., Pilon, F., Dogan, T., Cagnone, G., Patel, P., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.011 · Cited by 182
Targeting VEGF in eye neovascularization: What's new?
Amadio, M., Govoni, S. M., & Pascale, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.027 · Cited by 180
The Project MACULA retinal pigment epithelium grading system for histology and optical coherence tomography in age-related macular degeneration
Zanzottera, E. C., Messinger, J. D., Ach, T., Smith, R. T., Freund, K. B., & Curcio, C. A. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-16431 · Cited by 164
Imaging Features Associated with Progression to Geographic Atrophy in Age-Related Macular Degeneration
Jaffe, G. J., Chakravarthy, U., Freund, K. B., Guymer, R. H., Holz, F. G., Liakopoulos, S., Monés, J., Rosenfeld, P. J., Sadda, S. R., Sarraf, D., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.12.009 · Cited by 170
Self-citation
Age-Related Macular Degeneration
Apte, R. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2102061 · Cited by 174
Application of Automated Quantification of Fluid Volumes to Anti–VEGF Therapy of Neovascular Age-Related Macular Degeneration
Schmidt-Erfurth, U. M., Vogl, W., Jampol, L. M., & Bogunović, H. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.010 · Cited by 159
VEGF regulates local inhibitory complement proteins in the eye and kidney
Keir, L. S., Firth, R., Aponik, L., Feitelberg, D., Sakimoto, S., Aguilar, E., Welsh, G. I., Richards, A., Usui, Y., Satchell, S. C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86418 · Cited by 154
Neurovascular crosstalk between interneurons and capillaries is required for vision.
Usui, Y., Westenskow, P., Kurihara, T., Aguilar, E., Sakimoto, S., Paris, L. P., Wittgrove, C. M., Feitelberg, D., Friedlander, M., Moreno, S. K., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80297 · Cited by 155
Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.026 · Cited by 155
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration
Li, E., Donati, S., Lindsley, K. B., Krzystolik, M. G., & Virgili, G. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012208.pub2 · Cited by 143
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy
Babapoor-Farrokhran, S., Jee, K. J., Puchner, B., Hassan, S. J., Xin, X., Rodrigues, M. W., Kashiwabuchi, F., Ma, T., Hu, K., Deshpande, M. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423765112 · Cited by 138
Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration
Peden, M. C., Suñer, I. J., Hammer, M. E., & Grizzard, W. S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.018 · Cited by 131
Anti–Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease
Campochiaro, P. A., Aiello, L. P., & Rosenfeld, P. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.056 · Cited by 136
Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning
Moraes, G., Fu, D. J., Wilson, M., Khalid, H., Wagner, S. K., Korot, E., Ferraz, D., Faes, L., Kelly, C. J., Spitz, T., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.09.025 · Cited by 130
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration
Gillies, M. C., Hunyor, A. P., Arnold, J., Guymer, R. H., Wolf, S., Ng, P., Pecheur, F. L., & McAllister, I. L. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6776 · Cited by 129
Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD
Waldstein, S. M., Wright, J., Warburton, J., Margaron, P., Simader, C., & Schmidt-Erfurth, U. M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.013 · Cited by 132
Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents
Gemenetzi, M. K., Lotery, A. J., & Patel, P. J. (2016) · Eye · doi:10.1038/eye.2016.208 · Cited by 134
Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases
Campochiaro, P. A., & Akhlaq, A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100921 · Cited by 130
VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases
Le, Y.-Z. (2017) · Vision Research · doi:10.1016/j.visres.2017.05.005 · Cited by 124
Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration
Schaal, K. B., Rosenfeld, P. J., Gregori, G., Yehoshua, Z., & Feuer, W. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.034 · Cited by 115
Age-Related Macular Degeneration: Epidemiology and Clinical Aspects
Keenan, T. D. L., Cukras, C. A., & Chew, E. Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_1 · Cited by 119
Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration
Munk, M. R., Ceklic, L., Ebneter, A., Huf, W., Wolf, S., & Zinkernagel, M. S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13157 · Cited by 107
Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials
Zhou, Q., Daniel, E., Maguire, M. G., Grunwald, J. E., Martin, E. R., Martin, D. F., & Ying, G. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.043 · Cited by 108
Self-citation
Optical Coherence Tomography Predictors of Risk for Progression to Non-Neovascular Atrophic Age-Related Macular Degeneration
Sleiman, K., Pasricha, M. V., Winter, K. P., McCall, M. N., Yiu, G. C., Farsiu, S., Chew, E. Y., Clemons, T. E., Toth, C. A., Toth, C. A., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.06.032 · Cited by 108
Self-citation
GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Xu, L., Mrejen, S., Jung, J. J., Gallego‐Pinazo, R., Thompson, D., Marsiglia, M., & Freund, K. B. (2014) · Retina · doi:10.1097/iae.0000000000000374 · Cited by 108
Risk Factors for Geographic Atrophy After Intravitreal Ranibizumab Injections for Retinal Angiomatous Proliferation
Cho, H. J., Yoo, S. G., Kim, H. S., Kim, J. H., Kim, C. G., Lee, T. G., & Kim, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.10.035 · Cited by 102
Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study
Ting, D. S. W., Ng, W. Y., Ng, S. R., Tan, S. P., Yeo, I. Y. S., Mathur, R., Chan, C. M., Tan, A. C. S., Tan, G. S. W., Wong, T. Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.12.024 · Cited by 99
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
Arnold, J., Markey, C. M., Kurstjens, N., & Guymer, R. H. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0207-3 · Cited by 100
HIF-1α and HIF-2α redundantly promote retinal neovascularization in patients with ischemic retinal disease
Zhang, J., Qin, Y., Martinez, M., Flores-Bellver, M., Rodrigues, M., Dinabandhu, A., Cao, X., Deshpande, M., Qin, Y., Aparicio-Domingo, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139202 · Cited by 95
Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin
Smith, R., Ninchoji, T., Gordon, E. J., André, H., Dejana, E., Vestweber, D., Kvanta, A., & Claesson, L. (2020) · eLife · doi:10.7554/elife.54056 · Cited by 95
Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects
Danis, R. P., Lavine, J. A., & Domalpally, A. (2015) · Clinical ophthalmology · doi:10.2147/opth.s92359 · Cited by 100
Macular Atrophy in Neovascular Age-Related Macular Degeneration
Gillies, M. C., Hunyor, A. P., Arnold, J., Guymer, R. H., Wolf, S., Pecheur, F. L., Munk, M. R., & McAllister, I. L. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.08.023 · Cited by 92
Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic Therapy of Neovascular Age-Related Macular Degeneration
Schütze, C., Wedl, M., Baumann, B., Pircher, M., Hitzenberger, C. K. F., & Schmidt-Erfurth, U. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.02.020 · Cited by 90
Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19969 · Cited by 90
One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration
Arcinue, C. A., Ma, F., Barteselli, G., Sharpsten, L., Gomez, M. L., & Freeman, W. R. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.11.022 · Cited by 88
The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective
Mammadzada, P., Corredoira, P. M. F., & André, H. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03422-9 · Cited by 95
Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)
Bhisitkul, R. B., Desai, S. J., Boyer, D. S., Sadda, S. R., & Zhang, K. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.033 · Cited by 90
Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
Chandra, S., Arpa, C., Menon, D., Khalid, H., HAMILTON, R. D., Nicholson, L., Pal, B., Fasolo, S., Hykin, P. G., Keane, P. A., et al. (2020) · Eye · doi:10.1038/s41433-020-0764-9 · Cited by 88
Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions
Lipécz, Á., Miller, L. R., Kovács, I., Czakó, C. N., Csípő, T., Baffi, J., Csiszár, A., Tarantini, S., Ungvari, Z. I., Yabluchanskiy, A., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00138-3 · Cited by 88
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles
Tsujinaka, H., Fu, J., Shen, J., Yu, Y., Hafiz, Z., Kays, J. C., McKenzie, D. A., Cardona, D., Culp, D., Peterson, W. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14340-x · Cited by 89
Assessment of Neutrophil/Lymphocyte Ratio in Patients with Age-related Macular Degeneration
İlhan, N., Dağlıoğlu, M. C., İlhan, Ö., Çoşkun, M., Tuzcu, E. A., Kahraman, H., & Keskın, U. (2014) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.921715 · Cited by 89
Choriocapillaris Degeneration in Geographic Atrophy
Sohn, E. H., Flamme‐Wiese, M. J., Whitmore, S. S., Workalemahu, G., Marneros, A. G., Boese, E. A., Kwon, Y. H., Wang, K., Abràmoff, M. D., Tucker, B. A., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.04.005 · Cited by 83
GEOGRAPHIC ATROPHY
Schmitz-Valckenberg, S., Sadda, S. R., Staurenghi, G., Chew, E. Y., Fleckenstein, M., & Holz, F. G. (2016) · Retina · doi:10.1097/iae.0000000000001258 · Cited by 81
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R., & Goldinger, S. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.018 · Cited by 82
Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
Schauwvlieghe, A.-S. M. E., Dijkman, G., Hooymans, J. M. M., Verbraak, F. D., Hoyng, C. B., Dijkgraaf, M. G. W., Pető, T., Vingerling, J. R., & Schlingemann, R. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153052 · Cited by 87
Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over A Ten-Year Period
Hutton, D. W., Newman-Casey, P. A., Tavag, M., Zacks, D. N., & Stein, J. D. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.0832 · Cited by 79
Complement cascade inhibition in geographic atrophy: a review
Desai, D., & Dugel, P. U. (2022) · Eye · doi:10.1038/s41433-021-01765-x · Cited by 78
Evolution of Intravitreal Therapy for Retinal Diseases—From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 76
Self-citation
Laser Treatment for Diabetic Macular Edema in the 21st Century
Romero‐Aroca, P., Reyes-Torres, J., Baget‐Bernaldiz, M., & Blasco-Suñe, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140402123026 · Cited by 74
Retinal angiomatous proliferation
Tsai, A. S. H., Cheung, N., Gan, A. T. L., Jaffe, G. J., Sivaprasad, S., Wong, T. Y., & Cheung, C. M. G. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.01.008 · Cited by 74
Self-citation
Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration
Kim, J., Park, J. R., Choi, J., Park, I., Hwang, Y., Bae, H., Kim, Y., Choi, W., Yang, J. M., Han, S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau6732 · Cited by 72
Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.
Waugh, N., Loveman, E., Colquitt, J., Royle, P., Yeong, J., Hoad, G. V., & Lois, N. (2018) · Health Technology Assessment · doi:10.3310/hta22270 · Cited by 61
Idiopathic preretinal glia in aging and age-related macular degeneration
Edwards, M. M., McLeod, D. S., Bhutto, I. A., Villalonga, M. B., Seddon, J. M., & Lutty, G. A. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.07.016 · Cited by 70
Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
Mrejen, S., Jung, J. J., Chen, C., PATEL, S. N., Gallego‐Pinazo, R., Yannuzzi, N. A., Xu, L., Marsiglia, M., Boddu, S., & Freund, K. B. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4071380 · Cited by 70
An 8‐year follow‐up of anti‐vascular endothelial growth factor treatment with a treat‐and‐extend modality for neovascular age‐related macular degeneration
Berg, K., Roald, A. B., Navaratnam, J., & Bragadóttir, R. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13522 · Cited by 69
Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study
Jaffe, G. J., Schmitz-Valckenberg, S., Boyer, D. S., Heier, J. S., Wolf-Schnurrbusch, U. E. K., Staurenghi, G., Schmidt-Erfurth, U. M., & Holz, F. G. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.08.024 · Cited by 69
Self-citation
Metabolomics and Age-Related Macular Degeneration
Brown, C. N., Green, B., Thompson, R., den Hollander, A. I., & Lengyel, I. (2018) · Metabolites · doi:10.3390/metabo9010004 · Cited by 67
A Deep Learning Model for Segmentation of Geographic Atrophy to Study Its Long-Term Natural History
Liefers, B. J., Colijn, J. M., González-Gonzalo, C., Verzijden, T., Wang, J. J., Joachim, N., Mitchell, P. L. R., Hoyng, C. B., van Ginneken, B., Klaver, C. C. W., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.02.009 · Cited by 66
PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Kuppermann, B. D., Patel, S. S., Boyer, D. S., Augustin, A. J., Freeman, W. R., Kerr, K. J., Guo, Q., Schneider, S., López, F. J., & on behalf of the Brimo DDS Gen 1 Study Group (2020) · Retina · doi:10.1097/iae.0000000000002789 · Cited by 65
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration
Cheung, C. M. G., Grewal, D. S., Teo, K. Y. C., Gan, A. T. L., Mohla, A., Chakravarthy, U., Wong, T. Y., & Jaffe, G. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.06.002 · Cited by 65
Self-citation
Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration
Sadda, S. R., Abdelfattah, N. S., Lei, J., Shi, Y., Marion, K. M., Morgenthien, E. A., Gune, S., & Balasubramanian, S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.03.031 · Cited by 67
VISUALIZING RETINAL PIGMENT EPITHELIUM PHENOTYPES IN THE TRANSITION TO ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Zanzottera, E. C., Ach, T., Huisingh, C., Messinger, J. D., Freund, K. B., & Curcio, C. A. (2016) · Retina · doi:10.1097/iae.0000000000001330 · Cited by 63
Intralesional Macular Atrophy in Anti–Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial
Bailey, C., Scott, L. J., Rogers, C. A., Reeves, B. C., Hamill, B., Pető, T., Chakravarthy, U., & Harding, S. P. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.013 · Cited by 64
Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema
Guigou, S., Pommier, S., Meyer, F., Hajjar, C., Merite, P. Y., Parrat, É., Rouhette, H., Rebollo, O., & Matonti, F. (2015) · Ophthalmologica · doi:10.1159/000381356 · Cited by 63
Retinal pigment epithelium transplantation: concepts, challenges, and future prospects
Alexander, P., Thomson, H. A., Luff, A. J., & Lotery, A. J. (2015) · Eye · doi:10.1038/eye.2015.89 · Cited by 63
A Revised Hemodynamic Theory of Age-Related Macular Degeneration
Gelfand, B. D., & Ambati, J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.06.009 · Cited by 65
IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL
Wickremasinghe, S., Janakan, V., Sandhu, S. S., Islam, A. F. M., Abedi, F., & Guymer, R. H. (2015) · Retina · doi:10.1097/iae.0000000000000902 · Cited by 62
Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Cancarini, A., & Costagliola, C. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666151001120831 · Cited by 63
Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review
Kaszubski, P. A., Ami, T. B., Saade, C., & Smith, R. T. (2016) · Ophthalmic Research · doi:10.1159/000443209 · Cited by 62
Anti–Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration
Sadda, S. R., Guymer, R. H., Monés, J., Tufail, A., & Jaffe, G. J. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.11.010 · Cited by 61
Self-citation
Optical Coherence Tomography Angiography Reveals Mature, Tangled Vascular Networks in Eyes With Neovascular Age-Related Macular Degeneration Showing Resistance to Geographic Atrophy
Dansingani, K. K., & Freund, K. B. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20151008-02 · Cited by 61
Editing VEGFR2 Blocks VEGF-Induced Activation of Akt and Tube Formation
Huang, X., Zhou, G., Wu, W., Ma, G., D'Amore, P. A., Mukai, S., & Lei, H. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20537 · Cited by 61
INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group
Arevalo, J. F., Lasave, A. F., Wu, L., Acón, D., Berrocal, M. H., Diaz-Llopis, M., Gallego-Pinazo, R., Serrano, M. A., Alezzandrini, A. A., Rojas, S., et al. (2016) · Retina · doi:10.1097/iae.0000000000000827 · Cited by 60
PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Abdelfattah, N. S., Zhang, H., Boyer, D. S., & Sadda, S. R. (2016) · Retina · doi:10.1097/iae.0000000000001059 · Cited by 61
Anti-angiogenic Therapy for Retinal Disease
Paulus, Y. M., & Sodhi, A. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_78 · Cited by 60

Authors: Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., Martin, A. A., Hagstrom, S. A., & Martin, D. F.
Affiliations: University of Pennsylvania (US)
Duke University (US)
University of Colorado Anschutz (US)
University of Wisconsin–Madison (US)
Oregon Health & Science University (US)
Cleveland Clinic (US)
Corresponding author: Grunwald, Juan E.
ORCID: Grunwald, Juan E.
Daniel, Ebenezer
Huang, Jiayan
Ying, Gui-shuang
Maguire, Maureen G.
Toth, Cynthia A.
Jaffe, Glenn J.
Klein, Michael L.
Hagstrom, Stephanie A.
Martin, Daniel F.
Venue: Ophthalmology
Publisher: Elsevier BV
Published: 2014-01
Volume: 121
Issue: 1
Pages: 150-161
ISSN: 0161-6420 (ISSN-L)
DOI: 10.1016/j.ophtha.2013.08.015
PMC: PMC3892560
OpenAlex: W2131192872
Cited by: 590
References: 46
Citations by year: 2026: 17 · 2025: 30 · 2024: 33 · 2023: 26 · 2022: 32 · 2021: 45 · 2020: 68 · 2019: 55 · 2018: 48 · 2017: 57 · 2016: 79 · 2015: 70 · 2014: 30
FWCI: 58.79
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Ophthalmology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Eye Institute (U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828)
National Institutes of Health
Department of Health and Human Services
Topics: Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords: geographic atrophy, age-related macular degeneration, risk factors, ranibizumab, bevacizumab, anti-VEGF therapy, intravitreal injection, retinal angiomatous proliferation, subretinal fluid, visual acuity, choroidal neovascularization, retinal pigment epithelium
MeSH terms: Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Female, Fluorescein Angiography, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Visual Acuity, Cohort Studies, Incidence, Proportional Hazards Models, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Geographic Atrophy, Wet Macular Degeneration, Genotyping Techniques, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks